Oncogenic MicroRNAs: Key Players in Malignant Transformation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
MicroRNAs (miRNAs) represent a class of non-coding RNAs that exert pivotal roles in the regulation of gene expression at the post-transcriptional level. MiRNAs are involved in many biological processes and slight modulations in their expression have been correlated with the occurrence of different diseases. In particular, alterations in the expression of miRNAs with oncogenic or tumor suppressor functions have been associated with carcinogenesis, malignant transformation, metastasis and response to anticancer treatments. This review will mainly focus on oncogenic miRNAs whose aberrant expression leads to malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“Mutations in the TP53 gene are the most frequent type of gene-specific alterations in different human cancers [58].”
BackgroundApoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524 · cited 1×
“Defects in apoptotic pathway contribute to the occurrence of different human diseases, such as cancer [84].”
BackgroundCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · cited 1×
“The extrinsic pathway requires the activation of death receptors anchored at the cell membrane through the binding of FasL, TNF and TRAIL ligands, which cause the recruitment and the oligomerization of Fas-Associated protein with Death Domain (FADD) within the Death-Inducing Signaling Complex (DISC), resulting in Casp…”
BackgroundRegulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168 · cited 1×
“Alterations in DNA, caused by genetic mutations determining structural and expression modification, at coding and non-coding regions, are responsible for cancer occurrence, gradual increase in tumor size, disorganization and malignancy [1].”
BackgroundUnique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023 · cited 1×
“Several studies have identified miRNA expression profiles specific to different human cancer types that also correlate with patient survival, suggesting the potential usefulness of miRNAs in cancer prediction, diagnosis and therapy [133–135].”
BackgroundTumour invasion and metastasis initiated by microRNA-10b in breast cancer
Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06174 · Cited by 2,605 · cited 1×
“In particular, the expression of miR-10b is induced by the transcription factor Twist, which binds to the putative promoter of mir-10b [121].”
BackgroundTP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“Most of these mutations (90%) are missense mutations that mainly reside in the exons encoding the p53 DNA-binding domain [59].”
BackgroundThe p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967 · cited 1×
“p53 protein acts as a transcriptional activator and regulates the expression of many target genes involved in different cellular processes, such as cell cycle arrest, apoptosis, DNA repair and senescence [57].”
BackgroundAsangani, I. A., Rasheed, S. A. K., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., & Allgayer, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210856 · Cited by 1,882 · cited 1×
“Asangani and colleagues have demonstrated that miR-21 binds to Pdcd4 3’UTR determining its downregulation and consequentially an induction of invasion processes in colorectal cancer [119].”
BackgroundLindsten, T., Ross, A. J., King, A., Zong, W.-X., Rathmell, J. C., Shiels, H. A., Ulrich, E., Waymire, K. G., Mahar, P., Frauwirth, K., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00136-2 · Cited by 1,489 · cited 1×
“Activation of apoptotic pathway plays a key role in biological development and tissues homeostasis [83].”
BackgroundMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · cited 1×
“These mutations frequently cause a loss of wild-type p53 tumor suppressor activity, but at the same time, some of these mutant p53 proteins gain new oncogenic properties that favor insurgence, maintenance, spread of the tumor, and chemoresistance of malignant cells [60,61].”
BackgroundMicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y.-Y. (2008) · Cell Research · doi:10.1038/cr.2008.24 · Cited by 1,051 · cited 1×
“For example, miR-21 has a role not only in tumor growth, but also in invasion and tumor metastasis by targeting multiple tumor/metastasis suppressor genes such as TPM1, PDCD4 and Maspin in metastatic breast cancer [118].”
BackgroundA role for ATR in the DNA damage-induced phosphorylation of p53
Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S.-Y., Taya, Y., Prives, C., & Abraham, R. T. (1999) · Genes & Development · doi:10.1101/gad.13.2.152 · Cited by 1,046 · cited 1×
“DNA damage response requires either ATM or ATR proteins that have the ability to bind to damaged DNA and to activate p53 tumor suppressor protein that in turn leads to DNA repair, cell-cycle arrest or apoptosis, depending on the entity of the damage [80].”
BackgroundMeng, F., Henson, R., Lang, M., Wehbe, H., Maheshwari, S., Mendell, J. T., Jiang, J., Schmittgen, T. D., & Patel, T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.057 · Cited by 984
Mogilyansky, E., & Rigoutsos, I. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.125 · Cited by 889 · cited 1×
“Several studies reported that this cluster is often deregulated in hematopoietic and solid cancers such as colorectal cancer, head and neck cancers, pancreatic cancer, breast cancer, ovarian cancer, lung cancer, renal cancer, hepatocellular carcinoma and osteosarcoma [14].”
BackgroundHu, Z., Chen, X., Zhao, Y., Tian, T., Jin, G., Shu, Y., Chen, Y., Xu, L., Zen, K., Zhang, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9342 · Cited by 798 · cited 1×
“In non-small-cell lung cancer high serum levels of miR-486, miR-30d and miR-125, and low serum levels of miR-1 and miR-499 were associated with poor survival [140–142].”
BackgroundThe effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615 · cited 1×
“Alterations in the components of the DNA repair machinery is also associated with tumorigenesis and chemoresistance [79].”
BackgroundMicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression
Ivanovska, I., Ball, A. S., Diaz, R. L., Magnus, J. F., Kibukawa, M., Schelter, J. M., Kobayashi, S. V., Lim, L., Burchard, J., Jackson, A. L., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01977-07 · Cited by 561
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418 · cited 1×
“Up until now two different molecular mechanisms through which mutant p53 exerts its gain of function activity have been characterized: (a) even if mutant p53 is not able to bind to DNA, it can be recruited by different transcription factors on the promoter of its gene targets, different from those commonly recruited b…”
BackgroundSelf-citationRegulation of G2/M events by Cdc25A through phosphorylation‐dependent modulation of its stability
Mailand, N., Podtelejnikov, A. V., Groth, A., Mann, M., Bartek, J., & Lukas, J. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf567 · Cited by 315
p16INK4a Translation Suppressed by miR-24
Lal, A., Kim, H. H., Abdelmohsen, K., Kuwano, Y., Pullmann, R., Srikantan, S., Subrahmanyam, R., Martindale, J. L., Yang, X., Ahmed, F., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001864 · Cited by 268 · cited 3×
“It has been demonstrated that different oncogenic miRNAs have cell cycle inhibitors of the INK4 or Cip/Kip families as targets, determining an aberrant DNA damage response [37–43].”
BackgroundMicroRNA-520g Confers Drug Resistance by Regulating p21 Expression in Colorectal Cancer
Zhang, Y., Geng, L., Talmon, G., & Wang, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620252 · Cited by 100 · cited 2×
“In particular, miR-520g confers drug resistance by the inhibition of p21 expression [44].”
Background
Cited by
miRNAs in Cancer (Review of Literature)
Smolarz, B., Durczyński, A., Romanowicz, H., Szyłło, K., & Hogendorf, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052805 · Cited by 296
Rojas, A., Añazco, C., González, I., & Araya, P. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy012 · Cited by 82
Mao, W., Wang, K., Wu, Z., Xu, B., & Chen, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02114-2 · Cited by 48
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
(2025) · doi:10.3390/cancers17132102 · Cited by 44
Choi, K. H., Shin, C. H., Lee, W. J., Ji, H., & Kim, H. H. (2019) · Bioscience Reports · doi:10.1042/bsr20190634 · Cited by 42
Metadata
- Authors
- Frixa, T., Donzelli, S., & Blandino, G.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2015-12-18
- Volume
- 7
- Issue
- 4
- Pages
- 2466-2485
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2216377839
- Cited by
- 147
- References
- 24
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.